XFOR Research and Charts

XFOR - X4 Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-03)

Last 0.74	Change ⇓ -0.01 (0.00%)	Volume 2,125,663
	Open 0.78	High 0.79	Low 0.72

8EMA (Daily) 0.73	40EMA (Daily) 0.60	50EMA (Daily) 0.59	STO (Daily) 67.883	MACD Hist (Daily) 0.017
8EMA (Weekly) 0.622	40EMA (Weekly) 0.72	50EMA (Weekly) 0.77	STO (Weekly) 63.007	MACD Hist (Weekly) 0.086


Company Profile
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.